Cstone pharma aktie
WebFunding. CStone Pharmaceuticals has raised a total of $410M in funding over 2 rounds. Their latest funding was raised on May 9, 2024 from a Series B round. CStone Pharmaceuticals is registered under the ticker HKG:2616 . Their stock opened with HK$12.00 in its Feb 25, 2024 IPO. WebSuzhou, China, March 20th, 2024--CStone Pharmaceuticals (HKEX: 2616), a leading biopharmaceutical company focused on the research, development, and commercialization of innovative immuno-oncology ther... 15 2024-03. CStone Pharmaceuticals Reports 2024 Annual Results and Business Updates .
Cstone pharma aktie
Did you know?
WebMay 28, 2024 · Shanghai - CStone Pharmaceuticals Co., Ltd. ('CStone' or the 'Company', HKEX: 2616) today announced that the company released the pre-clinical data of its three pipeline products, i.e. CS1001 (anti-PD-L1 monoclonal antibody), CS3002 (CDK4/6 selective small molecule inhibitor) and CS3003 (HDAC6 selective small molecule inhibitor), in the … WebMOBVISTA INC. : Vorstellung des Unternehmens MOBVISTA INC., Aktionäre, Vorstände und Berufsbeschreibung, Finanzstärkerating, offizielle Mitteilungen, Kontaktdaten ...
WebCSTONE MEDIA For Mainland Chinese Media: Jasmine Yang (MSL) +86 218 025 3296 [email protected] For International Media: Daniel Del Re (Kekst CNC) + 852 9212 3105 [email protected] WebGet the latest CStone Pharmaceuticals (2616) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and …
WebJun 7, 2024 · CStone Pharmaceuticals (OTCPK:CSPHF) (2616.HK) revenue fell 77% last year and its net loss climbed, as the Chinese drug company saw one-off license fees decline sharply and marketing costs to ... WebCStone Pharmaceuticals (HKEX: 2616), a leading biopharmaceutical company focusing on the research, development and commercialization of innovative immuno-oncology …
WebCStone Pharmaceuticals 6,317 followers on LinkedIn. 拓新药时代，筑健康基石 Lead the Era of Drug Innovation, Be the Cornerstone of Health CStone (HKEX: 2616) is a biopharmaceutical ...
WebMar 23, 2024 · 20.03. 13.03. CStone Pharmaceuticals ist eine in China ansässige Investment-Holding. Über seine Tochtergesellschaften ist das Unternehmen … high functioning autism prognosishigh functioning autism motor skillsWebFeb 24, 2024 · CStone Pharmaceuticals is a China-based investment holding company. Through its subsidiaries, the Company is primarily engaged in development, manufacturing and sales of biopharmaceutical products. Its main products include immuno-oncology drugs and molecularly targeted drugs. The Company conducts its businesses mainly in … high functioning autism relationshipsWebCSTONE PHARMACEUTICALS. Analyst Report: Amazon.com, Inc. Amazon is a leading online retailer and one of the highest-grossing e-commerce aggregators, with $386 billion … high-functioning autism personality traitsWebApr 6, 2024 · CStone Pharma annonce que les résultats d'une étude sur le traitement du lymphome ont é.. 03/31: CStone Pharmaceuticals annonce la publication des résultats de l'étude GEMSTONE-201 sur.. 03/24: CStone Pharmaceuticals attribue des unités d'actions restreintes et des options sur act.. 03/20 howick village optometristWebNov 21, 2024 · CStone Pharmaceuticals (HKEX: 2616) is a biopharmaceutical company focused on researching, developing, and commercializing innovative immuno-oncology and precision medicines to address the unmet medical needs of cancer patients in China and worldwide. Established in 2015, CStone has assembled a world-class management … high functioning autism quizWebMar 13, 2024 · Their share performances varied on Monday, with Broncus Holding Corporation advancing 4% while CStone Pharmaceuticals was down 2.2%. Further supporting sentiment, China reported unexpectedly strong credit growth for February, with money supply expanding at the fastest pace in nearly 7 years, as Beijing looked to … high functioning autism school